Prøve GULL - Gratis
Union Budget 2025 targets healthcare, medical education & Al, omitting medical devices.
Bio Spectrum
|March 2025
The overall macro-economic and policy direction measures announced in the Union Budget 2025, particularly focusing on cancer care, medical education, AI, R&D and innovation, is appreciable. There are many key points in the budget announcements that will strengthen the economy and propel the GDP growth. However, without any mention of investment promotion measures for the 70 per cent imports-dependent medical devices sector in the budget speech, industry disappointment was an expected reaction. Let's delve further.

Union Minister of Finance and Corporate Affairs Nirmala Sitharaman presented the Union Budget 2025-26 in Parliament on February 1, 2025. While multiple new initiatives within the healthcare sector were announced such as the establishment of new Day Care Cancer Centres in district hospitals; Full exemption from Basic Customs Duty of 36 lifesaving drugs and medicines for treating cancer, rare diseases and chronic diseases; addition of 10,000 seats in medical colleges and hospitals next year; Announcement of National Manufacturing Mission; Promotion of medical tourism etc., expectations of the Medical Devices sector have not been met.
The Indian Medical Devices Industry was expecting an increase in Custom Duty to a nominal 10 per cent to 15 per cent (and as a Predictable Tariff Policy); Correction of Inverted Duty by levying Health Cess of 5 per cent custom duty on balance Medical Devices; Trade Margin Capping by monitoring MRP of Imports; Income Tax benefits for CAPEX and R&D investments in Medical Devices. The industry was also hoping that the government could consider standardising the GST rate of 12 per cent across all medical devices as it would simplify the tax structure, ensuring consistency and ease of doing business.

Denne historien er fra March 2025-utgaven av Bio Spectrum.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Bio Spectrum

Bio Spectrum
WHO certifies Suriname malaria-free
Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).
1 min
August 2025

Bio Spectrum
Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation
Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.
1 min
August 2025
Bio Spectrum
Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab
Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.
1 min
August 2025
Bio Spectrum
Illumina buys SomaLogic for $425 M to accelerate proteomics business
Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.
1 min
August 2025

Bio Spectrum
Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26
Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.
1 min
August 2025
Bio Spectrum
WHO highlights risks associated with use of semaglutide medicines
The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.
1 min
August 2025

Bio Spectrum
Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin
Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.
1 min
August 2025

Bio Spectrum
AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru
AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.
1 min
August 2025

Bio Spectrum
Novo Nordisk launches injectable Semaglutide for weight management in India
Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.
1 min
August 2025

Bio Spectrum
Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?
India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.
12 mins
August 2025
Listen
Translate
Change font size